Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
NICE Endorses Dupilumab for Eosinophilic COPD Treatment
NICE Backs Dupilumab Eosinophilic COPD Option
Dupilumab eosinophilic COPD treatment gains momentum as the National Institute for Health and Care Excellence (NICE) final draft guidance recommends dupilumab as an add-on maintenance therap...
Accelerating FAST-EU Clinical Trials
FAST-EU Clinical Trials Launch with 70-Day Target
The FAST-EU clinical trials pilot, known as Facilitating and Accelerating Strategic Clinical Trials in the EU, is a one-year voluntary initiative by the
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment
NICE Backs Talazoparib-Enzalutamide for Advanced Prostate Cancer
The National Institute for Health and Care Excellence (NICE) has recommended talazoparib enzalutamide prostate cancer treatment, featuring talazoparib (...